SPY302.97-0.56 -0.18%
DIA254.35-1.42 -0.56%
IXIC9,368.99-43.37 -0.46%

Ultragenyx Pharmaceutical Q1 EPS $(2.050) Misses $(1.690) Estimate, Sales $36.300M Miss $36.580M Estimate

Ultragenyx Pharmaceutical (NASDAQ:RARE) reported quarterly losses of $(2.050) per share which missed the analyst consensus estimate of $(1.690) by 21.3 percent. This is a 12.64 percent decrease over losses of $(1.820)

Benzinga · 05/06/2020 20:23

Ultragenyx Pharmaceutical (NASDAQ:RARE) reported quarterly losses of $(2.050) per share which missed the analyst consensus estimate of $(1.690) by 21.3 percent. This is a 12.64 percent decrease over losses of $(1.820) per share from the same period last year. The company reported quarterly sales of $36.300 million which missed the analyst consensus estimate of $36.580 million by 0.77 percent. This is a 99.76 percent increase over sales of $18.172 million the same period last year.